Search results: Sage Journals

Open accessResearch articleFirst published July, 2021

SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis

Giedre Martus, Karin Bergling, Javier de Arteaga [...]

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Restricted accessResearch articleFirst published February, 2025

SGLT2 inhibition,circulating biomarkers,and Alzheimer's disease: A Mendelian randomization study

Hao Yang, Yuye Ning, Meilin Chen [...]

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2021

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series

Marko Škrtić, David Z. I. Cherney, Vikas S. Sridhar [...]

Canadian Journal of Kidney Health and Disease

Open accessResearch articleFirst published 2026

Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis

Jing Liu, Zipei Ma, Piaoran Liu [...]

Clinical and Applied Thrombosis/Hemostasis

Open accessResearch articleFirst published March, 2023

Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis

Giedre Martus, Karin Bergling, Carl M Öberg

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Open accessResearch articleFirst published 2019

How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology

Marcus May, Theodor Framke, Bernd Junker [...]

Therapeutic Advances in Endocrinology and Metabolism

Free accessResearch articleFirst published September, 2013

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin,a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

Mark Tirmenstein, Thomas E. Dorr, Evan B. Janovitz [...]

International Journal of Toxicology

Restricted accessResearch articleFirst published July, 2009

Dapagliflozin for the Treatment of Type 2 Diabetes

Amie McCord Brooks, Stacey M Thacker

Annals of Pharmacotherapy

Restricted accessEditorialFirst published March, 2023

SGLT2 inhibition,glucose transport and peritoneal dialysis: Finding the sweet spot

Vikas S Sridhar, Donald J Fraser

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Open accessReview articleFirst published 2021

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction

Michael V. Genuardi, Paul J. Mather

Therapeutic Advances in Cardiovascular Disease

Open accessResearch articleFirst published July, 2021

SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis

Giedre Martus, Karin Bergling, Javier de Arteaga [...]

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Restricted accessResearch articleFirst published February, 2025

SGLT2 inhibition,circulating biomarkers,and Alzheimer's disease: A Mendelian randomization study

Hao Yang, Yuye Ning, Meilin Chen [...]

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2021

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series

Marko Škrtić, David Z. I. Cherney, Vikas S. Sridhar [...]

Canadian Journal of Kidney Health and Disease

Open accessResearch articleFirst published 2026

Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis

Jing Liu, Zipei Ma, Piaoran Liu [...]

Clinical and Applied Thrombosis/Hemostasis

Open accessResearch articleFirst published March, 2023

Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis

Giedre Martus, Karin Bergling, Carl M Öberg

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Open accessResearch articleFirst published 2019

How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology

Marcus May, Theodor Framke, Bernd Junker [...]

Therapeutic Advances in Endocrinology and Metabolism

Free accessResearch articleFirst published September, 2013

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin,a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

Mark Tirmenstein, Thomas E. Dorr, Evan B. Janovitz [...]

International Journal of Toxicology

Restricted accessResearch articleFirst published July, 2009

Dapagliflozin for the Treatment of Type 2 Diabetes

Amie McCord Brooks, Stacey M Thacker

Annals of Pharmacotherapy

Restricted accessEditorialFirst published March, 2023

SGLT2 inhibition,glucose transport and peritoneal dialysis: Finding the sweet spot

Vikas S Sridhar, Donald J Fraser

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

Open accessReview articleFirst published 2021

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction

Michael V. Genuardi, Paul J. Mather

Therapeutic Advances in Cardiovascular Disease